REDMOD: pancreatic cancer signals in CT scans taken before diagnosis
Among nearly 2,000 abdominal CT scans originally considered normal, an AI radiomics model identified 73% of prediagnostic pancreatic cancers, with a median lead time of about 16 months. Validation included images from multiple institutions and protocols. This analysis used scans taken before diagnosis; clinical benefit and false positives in practice still need prospective evaluation.
Technology: REDMOD (Radiomics-based Early Detection Model)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: REDMOD was trained on 969 patients from a multi-institutional cohort and tested on an independent set of 493 patients (63 pre-diagnostic), with external specificity checks on further datasets and a comparison with radiologists; AUC 0.82 and 73.0% sensitivity, versus 38.9% for radiologists.
- Still unknown: The article states that prospective validation in high-risk cohorts is the necessary next step; no explicit limitations section.
- AI role: A fully automated radiomics framework with AI segmentation and an ensemble classifier on a 40-feature signature from standard-of-care CT scans.
Evidence sources: https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-ai-detects-pancreatic-cancer-up-to-3-years-before-diagnosis-in-landmark-validation-study/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1136/gutjnl-2025-337266&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.